Titre
Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Loyon, Romain
Auteure/Auteur
Jary, Marine
Auteure/Auteur
Salomé, Bérengère
Auteure/Auteur
Gomez-Cadena, Alejandra
Auteure/Auteur
Galaine, Jeanne
Auteure/Auteur
Kroemer, Marie
Auteure/Auteur
Romero, Pedro
Auteure/Auteur
Trabanelli, Sara
Auteure/Auteur
Adotévi, Olivier
Auteure/Auteur
Borg, Christophe
Auteure/Auteur
Jandus, Camilla
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1664-3224
Statut éditorial
Publié
Date de publication
2019-09-06
Volume
10
Première page
2121
Peer-reviewed
Oui
Langue
anglais
Résumé
Several distinct innate lymphoid cell (ILC) populations have been recently identified and shown to play a critical role in the immediate immune defense. In the context of tumors, there is evidence to support a dual role for ILCs with pro-or antitumor effects, depending on the ILC subset and the type of cancer. This ambivalent role has been particularly well-described in colorectal cancer models (CRC), but the presence and the evolution of ILCs in the peripheral blood of metastatic CRC (mCRC) patients have not yet been explored. Here, we investigated the distribution of ILC subsets in 96 mCRC patients who were prospectively included in the "Epitopes-CRCO2" trial. Peripheral bloodmononuclear cells (PBMCs) were analyzed by flow cytometry at metastatic diagnosis and after 3-months of treatment. The treatments consisted of Oxaliplatin-based chemotherapies for 76% of the patients or Folfiri (5FU, Irinotecan) chemotherapies for 14% of patients. Compared to healthy donors, the frequency of total ILCs was dramatically increased at metastatic diagnosis. CD56(+) ILC1-like cells were expanded, whereas ILC2, NCR- ILCP and NCR+ ILCP subsets were decreased. Combined analysis with the systemic anti-telomerase hTERT Th1 CD4 response revealed that patients with low anti-TERT Th1 CD4 responses had the highest frequencies of total ILCs at diagnosis. Of those, 91% had synchronous metastases, and their median progression-free survival was 7.43 months (vs. 9.17 months for the other patients). In these patients, ILC1 and ILC2 were significantly decreased, whereas CD56(+) ILC1-like cells were significantly increased compared to patients with low frequency of total ILCs and high anti-TERT responses. After treatment, the NCR+ ILCP were further decreased irrespective of the chemotherapy regimen, whereas the balance between ILC1 and CD56(+) ILC1-like cells was modulated mainly by the Folfiri regimen in favor of ILC1. Altogether our results describe the effects of different chemotherapies on ILCs in mCRC patients. We also establish for the first time a link between frequency of ILCs and anti-tumor CD4 T cell responses in cancer patients. Thus, our study supports an interest in monitoring ILCs during cancer therapy to possibly identify predictive biomarkers in mCRC.
PID Serval
serval:BIB_3FC0B4BB29C7
Open Access
Oui
Date de création
2019-09-23T17:38:05.322Z
Date de création dans IRIS
2025-05-20T20:22:43Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
31555301_BIB_3FC0B4BB29C7.pdf
Version du manuscrit
published
Licence
https://creativecommons.org/licenses/by/4.0
Taille
1.26 MB
Format
Adobe PDF
PID Serval
serval:BIB_3FC0B4BB29C7.P001
URN
urn:nbn:ch:serval-BIB_3FC0B4BB29C79
Somme de contrôle
(MD5):7b14a4694b6534a3b9797da9e6491ec4